Viberzi, with the active ingredient eluxadoline, is indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) [1]. It works by targeting the gastrointestinal tract to help manage symptoms associated with this condition [2].
How does Viberzi help with IBS-D?
Viberzi acts as a mixed mu-opioid receptor agonist and delta-opioid receptor antagonist, and a kappa-opioid receptor agonist [3]. This mechanism of action helps to reduce abdominal pain and improve bowel symptoms in patients with IBS-D [2]. The drug influences opioid receptors in the gut, which can affect gut motility and sensation [4].
Who is Viberzi prescribed for?
Viberzi is intended for adult patients who have been diagnosed with irritable bowel syndrome with diarrhea [1]. It is not for use in patients who have had a history of pancreatitis or who have severe liver problems [5]. The drug is also not recommended for patients with or without a gallbladder who have had severe constipation or bowel obstruction [5].
What are the potential side effects of Viberzi?
Common side effects associated with Viberzi include constipation, nausea, abdominal pain, and upper respiratory tract infection [6]. A serious side effect to be aware of is the risk of pancreatitis, particularly in patients who have had their gallbladder removed [5]. Sphincter of Oddi spasm is another potential adverse event [3]. Patients with IBS-D who do not have a gallbladder should not take Viberzi if they have had severe constipation or bowel obstruction [5].
When might Viberzi patents expire?
Patent information for Viberzi can be complex, often involving multiple patents covering the drug substance, manufacturing processes, and methods of use [7]. DrugPatentWatch.com tracks these patents, which can provide insights into when market exclusivity might end and generic versions could potentially become available [7].
Are there alternatives to Viberzi for IBS-D?
Several other medications are available to treat IBS-D, with varying mechanisms of action. These can include other opioid receptor modulators, antispasmodics, bile acid sequestrants, and probiotics, depending on the specific symptoms and patient profile [8]. The choice of treatment often depends on individual patient needs and response to therapy [8].